Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation
- PMID: 35404178
- DOI: 10.1080/07357907.2022.2065508
Predictive Value of Preoperative Neutrophil-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization Combined With Radiofrequency Ablation
Abstract
Purpose: To determine the predictive value of preoperative inflammatory markers in hepatocellular carcinoma (HCC) prognosis after transarterial chemoembolization (TACE) combined with radiofrequency ablation (RFA).
Materials and methods: A total of 161 patients with HCC who underwent TACE combined with RFA were enrolled in this retrospective study. Receiver operating characteristic (ROC) curve analysis was used to decide the cutoff value of the neutrophil-to-lymphocyte ratio (NLR), the lymphocyte-to-monocyte ratio (LMR), the platelet-to-lymphocyte ratio (PLR), and the prognostic nutritional index (PNI). The relationship between preoperative NLR, LMR, PLR, PNI, and survival outcomes was analyzed using Kaplan-Meier curves and multivariate Cox regression analyses.
Results: The cutoff value of NLR for the best discrimination of HCC prognosis was 2.95. The median recurrence-free survival (RFS) of the low NLR (≤2.95) group was longer than that of the high NLR (>2.95) group (29 months vs. 20 months, p = 0.013). The median overall survival (OS) of the low NLR group was longer than that of the high NLR group (60 months vs. 38 months, p = 0.006). Multivariate analysis showed that the tumor size (≤3 cm vs. >3cm), tumor number (single vs. multiple), and NLR (≤2.95 vs. >2.95) were independent predictors of the PFS and OS. LMR, PLR, and PNI did not have any prognostic significance.
Conclusion: NLR was confirmed as an independent predictive biomarker for hepatocellular carcinoma prognosis after TACE combined with RFA.
Keywords: Neutrophil-to-lymphocyte ratio; hepatocellular carcinoma; radiofrequency ablation; survival; transarterial chemoembolization.
Similar articles
-
Inflammation scores predict the survival of patients with hepatocellular carcinoma who were treated with transarterial chemoembolization and recombinant human type-5 adenovirus H101.PLoS One. 2017 Mar 29;12(3):e0174769. doi: 10.1371/journal.pone.0174769. eCollection 2017. PLoS One. 2017. PMID: 28355305 Free PMC article.
-
The predictive value of PIV, PLR, LMR, NPR, and NLR for the prognosis of transarterial chemoembolization in patients with hepatocellular carcinoma combined with liver cirrhosis.BMC Gastroenterol. 2025 Apr 29;25(1):315. doi: 10.1186/s12876-025-03815-0. BMC Gastroenterol. 2025. PMID: 40301803 Free PMC article.
-
Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma.Cancer Immunol Immunother. 2025 May 19;74(7):209. doi: 10.1007/s00262-025-04058-4. Cancer Immunol Immunother. 2025. PMID: 40387956 Free PMC article.
-
Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis.World J Surg Oncol. 2021 Mar 19;19(1):81. doi: 10.1186/s12957-021-02188-4. World J Surg Oncol. 2021. PMID: 33741001 Free PMC article. Review.
-
Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.Int J Hyperthermia. 2022;39(1):455-465. doi: 10.1080/02656736.2022.2048095. Int J Hyperthermia. 2022. PMID: 35271786
Cited by
-
Multisequence MRI-Based Radiomic Features Combined with Inflammatory Indices for Predicting the Overall Survival of HCC Patients After TACE.J Hepatocell Carcinoma. 2024 Oct 24;11:2049-2061. doi: 10.2147/JHC.S481301. eCollection 2024. J Hepatocell Carcinoma. 2024. PMID: 39469284 Free PMC article.
-
Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Front Oncol. 2023 Apr 18;13:1070019. doi: 10.3389/fonc.2023.1070019. eCollection 2023. Front Oncol. 2023. PMID: 37143942 Free PMC article.
-
Which is the best TACE agent for patients with different NLR hepatocellular carcinomas? A systematic review and network meta-analysis.Heliyon. 2024 May 4;10(9):e30759. doi: 10.1016/j.heliyon.2024.e30759. eCollection 2024 May 15. Heliyon. 2024. PMID: 38765170 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous